chlorambucil has been researched along with fludarabine phosphate in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Appelbaum, FR; Chapman, RA; Elias, L; Godwin, JE; Grever, MR; Head, DR; Metz, EN; Stock-Novack, D; Weick, JK | 1 |
| Begleiter, A; Liliemark, JO; Plunkett, W; Reed, JC | 1 |
| Bosanquet, AG; Daniel, PT; Dörken, B; Hummel, M; Sturm, I | 1 |
2 review(s) available for chlorambucil and fludarabine phosphate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Why do drugs work in CLL?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Chlorambucil; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Vidarabine Phosphate | 1996 |
1 trial(s) available for chlorambucil and fludarabine phosphate
| Article | Year |
|---|---|
A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Chlorambucil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Vidarabine Phosphate | 1993 |
3 other study(ies) available for chlorambucil and fludarabine phosphate
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis.
Topics: Aged; Antineoplastic Agents; Apoptosis; Arginine; Chlorambucil; Codon; Cyclophosphamide; DNA Mutational Analysis; Doxorubicin; Drug Resistance, Neoplasm; Female; Gamma Rays; Gene Expression Regulation, Neoplastic; Genes, p53; Homozygote; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Mutation; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Polymorphism, Single-Stranded Conformational; Prognosis; Proline; Vidarabine Phosphate; Vincristine | 2005 |